Gilead Sciences (GILD) CFO sells 3,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock in an open-market transaction. The sale took place on February 17, 2026, at an average price of $154.43 per share. After this sale, he directly owned 167,779 shares. The transaction was made under a Rule 10b5-1 trading plan adopted on August 29, 2024, and the share balance also reflects purchases through the company’s Employee Stock Purchase Plan.

Insider Trade Summary

Net Seller: 3,000 shares ($463,290)

Net Sell 1 txn

Insider Dickinson Andrew D

Role Chief Financial Officer

Sold 3,000 shs ($463K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,000	$154.43	$463K

Holdings After Transaction: Common Stock — 167,779 shares (Direct)

Footnotes (1)

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024. Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/17/2026		S(1)		3,000	D	$154.43	167,779(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on August 29, 2024.

2. Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

Remarks:

	/s/ Edward S. Son by Power of Attorney for Andrew D. Dickinson	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Gilead Sciences (GILD) report for Andrew D. Dickinson?

Gilead Sciences reported that Chief Financial Officer Andrew D. Dickinson sold 3,000 shares of common stock. The open-market sale occurred on February 17, 2026, and was executed at an average price of $154.43 per share.

How many Gilead Sciences (GILD) shares did Andrew D. Dickinson retain after the sale?

After the reported sale, Andrew D. Dickinson directly owned 167,779 Gilead Sciences shares. This post-transaction balance also reflects shares acquired through the Gilead Sciences, Inc. Employee Stock Purchase Plan, as described in the filing’s footnote.

Was the Gilead Sciences (GILD) CFO’s stock sale under a Rule 10b5-1 plan?

Yes. The sale of 3,000 Gilead Sciences shares by CFO Andrew D. Dickinson was made pursuant to a Rule 10b5-1 trading plan. The plan was adopted on August 29, 2024, providing a pre-arranged framework for selling shares over time.

What was the sale price for the Gilead Sciences (GILD) insider transaction?

The 3,000 Gilead Sciences shares sold by CFO Andrew D. Dickinson were transacted at an average price of $154.43 per share. This price reflects the weighted average for the open-market sale reported in the Form 4 filing.

Who is the insider involved in the latest Gilead Sciences (GILD) Form 4 filing?

The insider is Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. He reported an open-market sale of 3,000 shares of common stock and now directly holds 167,779 shares following this transaction.

Does the Form 4 mention employee stock purchase activity at Gilead Sciences (GILD)?

Yes. A footnote explains that Andrew D. Dickinson’s share balance was adjusted to include shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan, which affects the number of shares reported as owned after the sale.